Pharmacological activation of tumor suppressor, wild-type p53 as a promising strategy to fight cancer;Farmakologiczna aktywacja supresora nowotworu, natywnego białka p53 jako obiecuja̧ca strategia zwalczania nowotworów

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 64, Issue , 2010, Pages 396-407

  Sznarkowska, Alicja ^a   Olszewski, Robert ^a   Zawacka Pankau, Joanna ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Antitumor therapy; Apoptosis; Low molecular weight compounds; MDM2; p53 Tumor suppressor protein; p53 HDM2 complex; Proteasomal degradation

Indexed keywords

PROTEASOME; PROTEIN P53;

APOPTOSIS; HUMAN; METABOLISM; NEOPLASM; PHYSIOLOGY; REVIEW;

APOPTOSIS; HUMANS; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79952710527     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Bennett M., Macdonald K., Chan S. W., Luzio J. P., Simari R., Weissberg P.: Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science, 1998;282:290-293 (Pubitemid 28487200)
2. Berger M., Vogt Sionov R., Levine A. J., Haupt Y.: Role for the polyproline domain of p53 in its regulation by MDM2. J. Biol. Chem., 2001;276:3785-3790
3. Bond G. L., Hu W., Levine A. J.: MDM2 is a central node in the p53 pathway: 12 years and counting. Curr. Cancer Drug Targets, 2005;5:3-8 (Pubitemid 40321795)
4. Bossy-Wetzel E., Green D. R.: Apoptosis: checkpoint at the mitochondrial frontier. Mutat. Res., 1999;434:243-251 (Pubitemid 29352259)
5. Böttger A., Böttger V., Sparks A., Liu W. L., Howard S. F., Lane D. P.: Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol., 1997;1:860-869 (Pubitemid 27493125)
6. Brooks C. L., Gu W.: Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol., 2003;15:164-171 (Pubitemid 36332191)
7. Brown C. J., Lain S., Verma C. S., Fersht A. R., Lane D. P.: Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer, 2009;9:862-873
8. Cahilly-Snyder L., Yang-Feng T., Francke U., George D. L.: Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat. Cell Mol. Genet., 1987;13:235-244
9. Chan T. A., Hermeking H., Lengauer C., Kinzler K. W., Vogelstein B.: 14-3-3 sigma is required to prevent mitotic catastrophe after DNA damage. Nature, 1999;401:616-620
10. Chao C., Saito S., Kang J., Anderson C. W., Appella E., Xu Y.: p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage. EMBO J., 2000;19:4967-4975
11. Chène P.: Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat. Rev. Cancer, 2003;3:102-109 (Pubitemid 37328877)
12. Chène P., Fuchs J., Bohn J., García-Echeverría C., Furet P., Fabbro D.: A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines. J. Mol. Biol., 2000;299:245-253
13. Choong M. L., Yang H., Lee M. A., Lane D. P.: Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. Cell Cycle, 2009;8:2810-2818
14. Ding K., Lu Y., Nikolovska-Coleska Z., Qiu S., Ding Y., Gao W., Stuckey J., Krajewski K., Roller P. P., Tomita Y., Parrish D. A., Deschamps J. R., Wang S.: Structure-based design of potent non-peptide MDM2 inhibitors. J. Am. Chem. Soc, 2005;127:10130-10131 (Pubitemid 41045454)
15. Donehower L. A., Harvey M., Slagle B. L., McArthur M. J., Montgomery C. A. Jr., Butel J. S., Bradley A.: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature, 1992;356:215-221
16. Finlay C. A., Hinds P. W., Levine A. J.: The p53 protooncogene can act as a suppressor of transformation. Cell, 1989;57:1083-1093 (Pubitemid 19169804)
17. Freedman D. A., Wu L., Levine A. J.: Functions of the MDM2 oncoprotein. Cell. Mol. Life. Sci., 1999;55:96-107 (Pubitemid 29077858)
18. Gebow D., Miselis N., Liber H. L.: Homologous and nonhomologous recombination resulting in deletion: effects of p53 Status, microhomology, and repetitive DNA length and orientation. Mol. Cell. Biol., 2000;20:4028-4035 (Pubitemid 30314501)
19. Harms K. L., Chen X.: The C terminus of p53 family proteins is a cell fate determinant. Mol. Cell. Biol., 2005;25:2014-2030 (Pubitemid 40280163)
20. Hoh J., Jin S., Parrado T., Edington J., Levine A. J., Ott J.: The p53 MH algorithm and its application in detecting p53-responsive genes. Proc. Natl. Acad. Sci. USA, 2002;99:8467-8472 (Pubitemid 34693586)
21. Hsieh J. K., Chan F. S., O'Connor D. J., Mittnacht S., Zhong S., Lu X.: Rb regulates the stability and the apoptotic function of p53 via MDM2. Mol. Cell, 1999;3:181-193 (Pubitemid 29292619)
22. Issaeva N., Bozko P., Enge M., Protopopova M., Verhoef L. G., Masucci M., Pramanik A., Selivanova G.: Small molecule RITA binds to p53, blocks p53-HDM2 interaction and activates p53 function in tumors. Nat. Med., 2004;10:1321-1328 (Pubitemid 40022713)
23. Lain S., Hollick J. J., Campbell J., Staples O. D., Higgins M., Aoubala M., McCarthy A., Appleyard V., Murray K. E., Baker L., Thompson A., Mathers J., Holland S. J., Stark M. J., Pass G., Woods J., Lane D. P., Westwood N. J.: Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell., 2008;13:454-463 (Pubitemid 351609441)
24. Lane D. P., Crawford L. V.: T antigen is bound to a host protein in SV40-transformed cells. Nature, 1979;278:261-263 (Pubitemid 9129076)
25. Laptenko O., Prives C: Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ., 2006;13:951-961
26. Lin Y., Ma W., Benchimol S.: Pidd, a new death-domain - containing protein, is induced by p53 and promotes apoptosis. Nat. Genet., 2000;26:122-127
27. Linke S. P., Sengupta S., Khabie N., Jeffries B. A., Buchhop S., Miska S., Henning W., Pedeux R., Wang X. W., Hofseth L. J., Yang Q., Garfield S. H., Stürzbecher H. W., Harris C. C.: p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination. Cancer Res., 2003;63:2596-2605 (Pubitemid 36605201)
28. Marchenko N. D., Zaika A., Moll U. M.: Death signal-induced localization of p53 protein to mitochondria. J. Biol. Chem., 2000;275:16202-16212
29. Marine J. C., Francoz S., Maetens M., Wahl G., Toledo F., Lozano G.: Keeping p53 in check: Essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ., 2006;13:927-934
30. Mendrysa S. M., O'Leary K. A., McElwee M. K., Michalowski J., Eisenman R. N., Powell D. A., Perry M. E.: Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev., 2006;20:16-21 (Pubitemid 43042663)
31. Meulmeester E., Jochemsen A. G.: p53: a guide to apoptosis. Curr. Cancer Drug Targets, 2008;8:87-97 (Pubitemid 351347244)
32. Mitsunaga M., Tsubota A., Nariai K., Namiki Y., Sumi M., Yoshikawa T., Fujise K.: Early apoptosis and cell death induced by ATX-S10Na (II)-mediated photodynamic therapy are Bax-and p53-dependent in human colon cancer cells. World J. Gastroenterol., 2007;13:692-698
33. Momand J., Jung D., Wilczynski S., Niland J.: The MDM2 gene amplification database. Nucleic Acids Res., 1998;26:3453-3459 (Pubitemid 28347214)
34. Mutka S. C., Yang W. Q., Dong S. D., Ward S. L., Craig D. A., Timmermans P. B., Murli S.: Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res., 2009;69:510-517
35. Oda K., Arakawa H., Tanaka T., Matsuda K., Tanikawa C., Mori T., Nishimori H., Tamai K., Tokino T., Nakamura Y., Taya Y.: p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell, 2000;102:849-862
36. Oda E., Ohki R., Murasawa H., Nemoto J., Shibue T., Yamashita T., Tokino T., Taniguchi T., Tanaka N.: Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science, 2000;288:1053-1058 (Pubitemid 30324238)
37. Oren M., Levine A. J.: Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen. Proc. Natl. Acad. Sci. USA, 1983;80:56-59 (Pubitemid 13221825)
38. Sakaguchi K., Sakamoto H., Lewis M. S., Anderson C. W., Erickson J. W., Appella E., Xie D.: Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry, 1997;36:10117-10124 (Pubitemid 27357721)
39. Sakamuro D., Sabatini P., White E., Prendergast G. C.: The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene, 1997;15:887-898 (Pubitemid 27399550)
40. Senzer N., Nemunaitis J., Nemunaitis M., Lamont J., Gore M., Gabra H., Eeles R., Sodha N., Lynch F. J., Zumstein L. A., Menander K. B., Sobol R. E., Chada S.: p53 therapy in a patient with Li-Fraumeni syndrome. Mol. Cancer Ther., 2007;6:1478-1482 (Pubitemid 46954014)
41. Takimoto R., El-Deiry W. S.: Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene, 2000;19:1735-1743 (Pubitemid 30200979)
42. Tanimura S., Ohtsuka S., Mitsui K., Shirouzu K., Yoshimura A., Ohtsubo M.: MDM2 interacts with MDMX through their RING finger domains. FEBS Lett., 1999;447:5-9 (Pubitemid 29134936)
43. Toledo F., Wahl G. M.: Regulating the p53 pathway: In vitro hypotheses, in vitro veritas. Nat. Rev. Cancer, 2006;6:909-923 (Pubitemid 44862676)
44. Toledo F., Wahl G. M.: MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int. J. Biochem. Cell Biol., 2007;39:1476-1482 (Pubitemid 47031042)
45. Vassilev L. T.: MDM2 inhibitors for cancer therapy. Trends Mol. Med., 2007;13:23-31 (Pubitemid 46027725)
46. Vassilev L. T., Vu B. T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., Liu E. A.: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 2004;303:844-848 (Pubitemid 38174664)
47. Venot C., Maratrat M., Dereuil C., Conseiller E., Bracco L., Debussche L.: The requirement for the p53 proline-rich functioal domain for mediation of apoptosis is correlated with specific PIG3 gene. EMBO J., 1998;17:4668-4679 (Pubitemid 28377167)
48. Ventura A., Kirsch D. G., McLaughlin M. E., Tuveson D. A., Grimm J., Lintault L., Newman J., Reczek E. E., Weissleder R., Jacks T.: Restoration of p53 function leads to tumour regression in vivo. Nature, 2007;445:661-665 (Pubitemid 46232887)
49. Vousden K. H., Lu X.: Live or let die: the cell's response to p53. Nat. Rev. Cancer, 2002;2:594-604 (Pubitemid 37328926)
50. Wani M. A., Zhu Q. Z., El-Mahdy M., Wani A. A.: Influence of p53 tumor suppressor protein on bias of DNA repair and apoptotic response in human cells. Carcinogenesis, 1999;20:765-772 (Pubitemid 29191857)
51. Waterman M. J., Stavridi E. S., Waterman J. L., Halazonetis T. D.: ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat. Gen., 1998;19:175-178 (Pubitemid 28248801)
52. Yonish-Rouach E., Resnitzky D., Lotem J., Sachs L., Kimchi A., Oren M.: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature, 1999;352:345-347
53. Yu J., Zhang L., Hwang P. M., Kinzler K. W., Vogelstein B.: PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell., 2001;3:673-682 (Pubitemid 32706358)
54. Zawacka-Pankau J., Issaeva N., Hossain S., Pramanik A., Selivanova G., Podhajska A. J.: Protoporphyrin IX interacts with wild-type p53 protein in vitro and induces cell death of human colon cancer cells in a p53-dependent and-independent manner. J. Biol. Chem., 2007;282:2466-2472 (Pubitemid 47076795)
55. Zawacka-Pankau J., Kostecka A., Sznarkowska A., Hedström E., Kawiak A.: p73 tumor suppressor protein: A close relative of p53 not only in structure but also in anti-cancer approach? Cell Cycle, 2010;9:720-728
56. Zawacka-Pankau J., Krachulec J., Grulkowski I., Bielawski K. P., Selivanova G.: The p53-mediated cytotoxicity of photodynamic therapy of cancer: recent advances. Toxicol. Appl. Pharmacol., 2008;232:487-497
57. Zawacka-Pankau J., Maleńczyk K., Sznarkowska A.: The structure and cellular regulation of p73: Their implication in anticancer therapy. Postepy Hig. Med. Dosw., 2010;64:78-86
58. Zurer I., Hofseth L. J., Cohen Y., Xu-Welliver M., Hussain S. P., Harris C. C., Rotter V: The role of p53 in base excision repair following genotoxic stress. Carcinogenesis, 2004;25:11-19 (Pubitemid 38139225)